ANL vs AZN

Adlai Nortye Ltd. (ANL) exhibits severe financial distress, as evidenced by a Piotroski F-Score of 1/9—indicating weak operational and financial health—alongside a dangerously high Debt/Equity ratio of 5.63 and negative ROE of -138.98%. The company shows no profitability, with zero margins and negative earnings, while its Price/Book ratio of 36.98 suggests extreme overvaluation relative to book value. Despite a recent 1Y return of +247.2%, this surge appears speculative rather than fundamentals-driven, with no analyst consensus and no dividend or cash flow generation. The absence of key valuation metrics and the lack of sustainable growth signals make the current price unsustainable.

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.